Matt S. Anderson
Merck Research Labs
Merck & Co.
Inc., Whitehouse Station
NJ 07065-0900
USA
Name/email consistency: high
- Effect of raltegravir on estradiol and norgestimate plasma pharmacokinetics following oral contraceptive administration in healthy women. Anderson, M.S., Hanley, W.D., Moreau, A.R., Jin, B., Bieberdorf, F.A., Kost, J.T., Wenning, L.A., Stone, J.A., Wagner, J.A., Iwamoto, M. Br. J. Clin. Pharmacol (2011)
- Effect of raltegravir on the pharmacokinetics of methadone. Anderson, M.S., Mabalot Luk, J.A., Hanley, W.D., Jin, B., Riesenberg, R.A., Wenning, L.A., Chodakewitz, J.A., Wagner, J.A., Iwamoto, M. J. Clin. Pharmacol (2010)
- Minimal pharmacokinetic interaction between the human immunodeficiency virus nonnucleoside reverse transcriptase inhibitor etravirine and the integrase inhibitor raltegravir in healthy subjects. Anderson, M.S., Kakuda, T.N., Hanley, W., Miller, J., Kost, J.T., Stoltz, R., Wenning, L.A., Stone, J.A., Hoetelmans, R.M., Wagner, J.A., Iwamoto, M. Antimicrob. Agents Chemother. (2008)
- Conserved cytoplasmic motifs that distinguish sub-groups of the polyprenol phosphate:N-acetylhexosamine-1-phosphate transferase family. Anderson, M.S., Eveland, S.S., Price, N.P. FEMS Microbiol. Lett. (2000)
- Kinetic mechanism of the Escherichia coli UDPMurNAc-tripeptide D-alanyl-D-alanine-adding enzyme: use of a glutathione S-transferase fusion. Anderson, M.S., Eveland, S.S., Onishi, H.R., Pompliano, D.L. Biochemistry (1996)